Dear Colleagues,

Inflammatory bowel disease (IBD) is a chronic, frequently progressive condition that approximately affects from 1 to 1.3 million people in the United States.1 There is substantial room for improvement in the care of patients with IBD, as evidenced by a recent study of insurance claims that showed that approximately 80% of 32,883 patients with IBD received suboptimal therapy.2 Patient outcomes in IBD are diminished by multiple factors, including uncertainty about approaches to diagnosis, assessment, and treatment and a lack of knowledge about available therapies.

In order to meet the persistent challenges associated with IBD management, health care professionals must be knowledgeable about the evidence-based and expert-recommended strategies in the treatment of IBD in order to avoid disease flares, prevent structural damage and disability, and restore quality of life.

I invite you to participate in IBD Forum 2017, a unique continuing medical education program coming to an area near you this fall. The half-day session is designed to bring gastroenterologists and other health care professionals involved in the treatment of patients with IBD together with a nationally recognized faculty to address the most important challenges we currently face in 2017. The program will be both comprehensive and interactive with special sections reserved for case presentations, panel discussions, and audience participation.

We look forward to seeing you at this year’s program!

With best regards,
2017 Steering Committee
Stephen B. Hanauer, MD
Gary R. Lichtenstein, MD
William J. Sandborn, MD

1Epidemiology of the IBD - Inflammatory Bowel Disease. Centers for Disease Control and Prevention.
2Rubin DT, Mody R, Davis KL, Wang C-C. Aliment Pharmacol Ther. 2014;39(10):1143-1155.

iPad® is a trademark of Apple Inc., registered in the U.S. and other countries.

Copyright © Vindico Medical Education | Privacy Policy
856.994.9400 | 6900 Grove Road, Building 100 | Thorofare, New Jersey 08086
A Wyanoke Group Company